Full text is available at the source.
Abstract
Sodium-glucose cotransporter inhibitors, glucagon-like peptide 1 receptor agonists, and mineralocorticoid receptor blockers may provide substantial cardiovascular and renal protection in type 1 diabetes.
- These newer agents have revolutionized treatment for type 2 diabetes.
- Data on the effects of these agents in type 1 diabetes is summarized.
- There is an emphasis on the need for more long-term studies.
- Future studies could assess the impact of these agents on cardiovascular risk.
Simplified